Hormonal
Menstrual cycle phase has a trivial effect on exercise performance in eumenorrheic women, with no evidence supporting general guidelines for modulating training across phases.
Stop tracking your menstrual cycle to schedule workouts. The science shows that performance differences across phases are trivial and inconsistent. Instead of trying to align your training with your hormones, focus on consistent training habits. If you notice a personal pattern where you feel weaker or stronger in a specific phase, adjust your expectations for that specific session, but do not change your overall training plan based on the calendar.
The results from this systematic review and meta-analysis indicate that exercise performance might be trivially reduced during the early follicular phase of the MC, compared to all other phases. Due to the trivial effect size, the large between-study variation and the number of poor-quality studies included in this review, general guidelines on exercise performance across the MC cannot be formed; rather, it is recommended that a personalised approach should be taken based on each individual’s response to exercise performance across the MC.
Why this rating
The review itself is high quality (systematic/meta-analysis), but the underlying evidence base is rated 'low' due to methodological issues in primary studies.
Source
The Effects of Menstrual Cycle Phase on Exercise Performance in Eumenorrheic Women: A Systematic Review and Meta-Analysis
Kelly L. McNulty et al. · Sports Medicine · 2020
DOI 10.1007/s40279-020-01319-3
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →